Skip to main content
main-content
Erschienen in: Der Nervenarzt 6/2008

01.06.2008 | Amyotrophe Lateralsklerose | Übersichten

Amyotrophe Lateralsklerose

Aktuelle klinische Studien und ihr pathogenetischer Hintergrund

verfasst von: Dr. K. Kollewe, R. Dengler, S. Petri

Erschienen in: Der Nervenarzt | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die amyotrophe Lateralsklerose (ALS) ist eine neurodegenerative Erkrankung, die innerhalb von 3–5 Jahren zum Tode führt. Die bisher einzige Substanz mit marginalem therapeutischem Potenzial ist der Glutamatantagonist Riluzol, der jedoch nur zu einer durchschnittlichen Lebensverlängerung von 3–4 Monaten führt. Daher hat die symptomatische Therapie einen hohen Stellenwert. In zahlreichen tierexperimentellen und klinischen Studien werden potenziell neuroprotektive Wirkstoffe für eine kausale Behandlung untersucht. In diesem Übersichtsartikel sollen im Kontext mit den zugrunde liegenden Wirkmechanismen aktuelle klinischen ALS-Studien vorgestellt werden.
Literatur
1.
Zurück zum Zitat Almer G, Guegan C, Teismann P et al. (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49: 176–185 PubMedCrossRef Almer G, Guegan C, Teismann P et al. (2001) Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 49: 176–185 PubMedCrossRef
2.
Zurück zum Zitat Almer G, Teismann P, Stevic Z et al. (2002) Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58: 1277–1279 PubMed Almer G, Teismann P, Stevic Z et al. (2002) Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 58: 1277–1279 PubMed
3.
Zurück zum Zitat Angelov DN, Waibel S, Guntinas-Lichius O et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100: 4790–4795 PubMedCrossRef Angelov DN, Waibel S, Guntinas-Lichius O et al. (2003) Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 100: 4790–4795 PubMedCrossRef
4.
Zurück zum Zitat Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357–366 PubMedCrossRef Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357–366 PubMedCrossRef
5.
Zurück zum Zitat Beal MF, Ferrante RJ, Browne SE et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644–654 PubMedCrossRef Beal MF, Ferrante RJ, Browne SE et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644–654 PubMedCrossRef
6.
Zurück zum Zitat Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585–591 PubMedCrossRef Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330: 585–591 PubMedCrossRef
7.
Zurück zum Zitat Borasio GD, Robberecht W, Leigh PN et al. (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51: 583–586 PubMed Borasio GD, Robberecht W, Leigh PN et al. (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51: 583–586 PubMed
8.
Zurück zum Zitat Bowling AC, Schulz JB, Brown RH Jr, Beal MF (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61: 2322–2325 PubMedCrossRef Bowling AC, Schulz JB, Brown RH Jr, Beal MF (1993) Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 61: 2322–2325 PubMedCrossRef
9.
Zurück zum Zitat Brooks B, Sanjak M, Roelke K et al. (2005) Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in ALS: sensitivity analyses of discordance between survival and fucitonal outcomes with long-term follow-up. Amyotroph Lateral Scler Other Motor Neuron Disord [Suppl 1] 6: 118 Brooks B, Sanjak M, Roelke K et al. (2005) Phase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in ALS: sensitivity analyses of discordance between survival and fucitonal outcomes with long-term follow-up. Amyotroph Lateral Scler Other Motor Neuron Disord [Suppl 1] 6: 118
10.
Zurück zum Zitat Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723–749 PubMedCrossRef Bruijn LI, Miller TM, Cleveland DW (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723–749 PubMedCrossRef
11.
Zurück zum Zitat Carri MT, Grignaschi G, Bendotti C (2006) Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27: 267–273 PubMedCrossRef Carri MT, Grignaschi G, Bendotti C (2006) Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 27: 267–273 PubMedCrossRef
12.
Zurück zum Zitat Chou SM, Wang HS, Taniguchi A, Bucala R (1998) Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Medicine 4: 324–332 Chou SM, Wang HS, Taniguchi A, Bucala R (1998) Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Medicine 4: 324–332
13.
Zurück zum Zitat Clement AM, Nguyen MD, Roberts EA et al. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113–117 PubMedCrossRef Clement AM, Nguyen MD, Roberts EA et al. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113–117 PubMedCrossRef
14.
Zurück zum Zitat Crow JP, Calingasan NY, Chen J et al. (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258–265 PubMedCrossRef Crow JP, Calingasan NY, Chen J et al. (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258–265 PubMedCrossRef
15.
Zurück zum Zitat Cudkowicz M, Shefner, J, Simpson E et al. (2006) A multicenter, dose ranging safety and pharmacokinetics study of arimoclomol in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 7: 113 Cudkowicz M, Shefner, J, Simpson E et al. (2006) A multicenter, dose ranging safety and pharmacokinetics study of arimoclomol in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 7: 113
16.
Zurück zum Zitat Danzeisen R, Schwalenstoecker B, Gillardon F et al. (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316: 189–199 PubMedCrossRef Danzeisen R, Schwalenstoecker B, Gillardon F et al. (2006) Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 316: 189–199 PubMedCrossRef
17.
Zurück zum Zitat Di Giorgio FP, Carrasco MA, Siao MC et al. (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608–614 CrossRef Di Giorgio FP, Carrasco MA, Siao MC et al. (2007) Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608–614 CrossRef
18.
Zurück zum Zitat Do TQ, Schultz JR, Clarke CF (1996) Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proc Natl Acad Sci U S A 93: 7534–7539 PubMedCrossRef Do TQ, Schultz JR, Clarke CF (1996) Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids. Proc Natl Acad Sci U S A 93: 7534–7539 PubMedCrossRef
19.
Zurück zum Zitat Dobrowolny G, Giacinti C, Pelosi L et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168: 193–199 PubMedCrossRef Dobrowolny G, Giacinti C, Pelosi L et al. (2005) Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 168: 193–199 PubMedCrossRef
20.
Zurück zum Zitat Drachman DB, Frank K, Dykes-Hoberg M et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771–778 PubMedCrossRef Drachman DB, Frank K, Dykes-Hoberg M et al. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 52: 771–778 PubMedCrossRef
21.
Zurück zum Zitat Ferrante KL, Shefner J, Zhang H et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834–1836 PubMedCrossRef Ferrante KL, Shefner J, Zhang H et al. (2005) Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834–1836 PubMedCrossRef
22.
Zurück zum Zitat Ferrante RJ, Browne SE, Shinobu LA et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064–2074 PubMedCrossRef Ferrante RJ, Browne SE, Shinobu LA et al. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064–2074 PubMedCrossRef
23.
Zurück zum Zitat Ferrante RJ, Shinobu LA, Schulz JB et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326–334 PubMedCrossRef Ferrante RJ, Shinobu LA, Schulz JB et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326–334 PubMedCrossRef
24.
Zurück zum Zitat Gordon PH, Moore DH, Gelinas DF et al. (2004) Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62: 1845–1847 PubMed Gordon PH, Moore DH, Gelinas DF et al. (2004) Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62: 1845–1847 PubMed
25.
Zurück zum Zitat Greig NH, Mattson MP, Perry T et al. (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1035: 290–315 PubMedCrossRef Greig NH, Mattson MP, Perry T et al. (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Ann N Y Acad Sci 1035: 290–315 PubMedCrossRef
26.
Zurück zum Zitat Guegan C, Vila M, Rosoklija G et al. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 21: 6569–6576 PubMed Guegan C, Vila M, Rosoklija G et al. (2001) Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 21: 6569–6576 PubMed
27.
Zurück zum Zitat Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA (2000) Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 30: 205–207 PubMedCrossRef Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA (2000) Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 30: 205–207 PubMedCrossRef
28.
Zurück zum Zitat Gurney ME, Cutting FB, Zhai P et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157 PubMedCrossRef Gurney ME, Cutting FB, Zhai P et al. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157 PubMedCrossRef
29.
Zurück zum Zitat Hargitai J, Lewis H, Boros I et al. (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307: 689–695 PubMedCrossRef Hargitai J, Lewis H, Boros I et al. (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307: 689–695 PubMedCrossRef
30.
Zurück zum Zitat Haverkamp LJ, Smith RG, Appel SH (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 36: 253–254 PubMedCrossRef Haverkamp LJ, Smith RG, Appel SH (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 36: 253–254 PubMedCrossRef
31.
Zurück zum Zitat Henkel JS, Engelhardt JI, Siklos L et al. (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221–235 PubMedCrossRef Henkel JS, Engelhardt JI, Siklos L et al. (2004) Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221–235 PubMedCrossRef
32.
Zurück zum Zitat Hensley K, Fedynyshyn J, Ferrell S et al. (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74–80 PubMedCrossRef Hensley K, Fedynyshyn J, Ferrell S et al. (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74–80 PubMedCrossRef
33.
Zurück zum Zitat Hensley K, Floyd RA, Gordon B et al. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82: 365–374 PubMedCrossRef Hensley K, Floyd RA, Gordon B et al. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem 82: 365–374 PubMedCrossRef
34.
Zurück zum Zitat Hu JH, Zhang H, Wagey R et al. (2003) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 85: 432–442 PubMedCrossRef Hu JH, Zhang H, Wagey R et al. (2003) Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J Neurochem 85: 432–442 PubMedCrossRef
35.
Zurück zum Zitat Kaspar BK, Llado J, Sherkat N et al. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839–842 PubMedCrossRef Kaspar BK, Llado J, Sherkat N et al. (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839–842 PubMedCrossRef
36.
Zurück zum Zitat Katsumata S, Tateishi N, Kagamiishi Y et al. (1999) Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultered astrocytes and ischemic brain. Soc Neurosci 11: 843 (Abstr) Katsumata S, Tateishi N, Kagamiishi Y et al. (1999) Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultered astrocytes and ischemic brain. Soc Neurosci 11: 843 (Abstr)
37.
Zurück zum Zitat Kiaei M, Kipiani K, Petri S et al. (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegen Dis 2: 246–254 CrossRef Kiaei M, Kipiani K, Petri S et al. (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegen Dis 2: 246–254 CrossRef
38.
Zurück zum Zitat Kiaei M, Petri S, Kipiani K et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26: 2467–2473 PubMedCrossRef Kiaei M, Petri S, Kipiani K et al. (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26: 2467–2473 PubMedCrossRef
39.
Zurück zum Zitat Kieran D, Kalmar B, Dick JR et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402–405 PubMedCrossRef Kieran D, Kalmar B, Dick JR et al. (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10: 402–405 PubMedCrossRef
40.
Zurück zum Zitat Klivenyi P, Kiaei M, Gardian G et al. (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88: 576–582 PubMedCrossRef Klivenyi P, Kiaei M, Gardian G et al. (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88: 576–582 PubMedCrossRef
41.
Zurück zum Zitat Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139 PubMedCrossRef Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195: 137–139 PubMedCrossRef
42.
Zurück zum Zitat Kriz J, Nguyen MD, Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268–278 PubMedCrossRef Kriz J, Nguyen MD, Julien JP (2002) Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268–278 PubMedCrossRef
43.
Zurück zum Zitat Lacomblez L, Bensimon G, Leigh PN et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425–1431 PubMed Lacomblez L, Bensimon G, Leigh PN et al. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425–1431 PubMed
44.
Zurück zum Zitat Lai EC, Felice KJ, Festoff BW et al. (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49: 1621–1630 PubMed Lai EC, Felice KJ, Festoff BW et al. (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49: 1621–1630 PubMed
45.
Zurück zum Zitat Lambrechts D, Lafuste P, Carmeliet P, Conway EM (2006) Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends Mol Med 12: 345–347 PubMedCrossRef Lambrechts D, Lafuste P, Carmeliet P, Conway EM (2006) Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends Mol Med 12: 345–347 PubMedCrossRef
46.
Zurück zum Zitat Mackenzie IR, Bigio EH, Ince PG et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61: 427–434 PubMedCrossRef Mackenzie IR, Bigio EH, Ince PG et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61: 427–434 PubMedCrossRef
47.
Zurück zum Zitat Matthews RT, Yang L, Browne S et al. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892–8897 PubMedCrossRef Matthews RT, Yang L, Browne S et al. (1998) Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A 95: 8892–8897 PubMedCrossRef
48.
Zurück zum Zitat Mercuri E, Bertini E, Messina S et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14: 130–135 PubMedCrossRef Mercuri E, Bertini E, Messina S et al. (2004) Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 14: 130–135 PubMedCrossRef
49.
Zurück zum Zitat Meyer T MA, Borisow N, Dullinger J et al. (2007) Thalidomide causes sinus bradycardia in ALS. Akt Neurol 34: 69 Meyer T MA, Borisow N, Dullinger J et al. (2007) Thalidomide causes sinus bradycardia in ALS. Akt Neurol 34: 69
50.
Zurück zum Zitat Nagai M, Re DB, Nagata T et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615–622 PubMedCrossRef Nagai M, Re DB, Nagata T et al. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10: 615–622 PubMedCrossRef
51.
Zurück zum Zitat Neumann M, Sampathu DM, Kwong LK et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133 PubMedCrossRef Neumann M, Sampathu DM, Kwong LK et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130–133 PubMedCrossRef
52.
Zurück zum Zitat Nilsson M, Hansson E, Ronnback L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17: 327–332 PubMedCrossRef Nilsson M, Hansson E, Ronnback L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17: 327–332 PubMedCrossRef
53.
Zurück zum Zitat Oteiza PI, Uchitel OD, Carrasquedo F et al. (1997) Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 22: 535–539 PubMedCrossRef Oteiza PI, Uchitel OD, Carrasquedo F et al. (1997) Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 22: 535–539 PubMedCrossRef
54.
Zurück zum Zitat Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW (2000) Caspase-1 and −3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 97: 13901–13906 PubMedCrossRef Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW (2000) Caspase-1 and −3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 97: 13901–13906 PubMedCrossRef
55.
Zurück zum Zitat Patel M, Day BJ (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 20: 359–364 PubMedCrossRef Patel M, Day BJ (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci 20: 359–364 PubMedCrossRef
56.
Zurück zum Zitat Petri S, Kiaei M, Kipiani K et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40–49 PubMedCrossRef Petri S, Kiaei M, Kipiani K et al. (2006) Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40–49 PubMedCrossRef
57.
Zurück zum Zitat Rosen DR, Siddique T, Patterson D et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62 PubMedCrossRef Rosen DR, Siddique T, Patterson D et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62 PubMedCrossRef
58.
Zurück zum Zitat Rothstein JD, Van Kammen M, Levey AI et al. (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84 PubMedCrossRef Rothstein JD, Van Kammen M, Levey AI et al. (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84 PubMedCrossRef
59.
60.
Zurück zum Zitat Ryu H, Smith K, Camelo SI et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087–1098 PubMedCrossRef Ryu H, Smith K, Camelo SI et al. (2005) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087–1098 PubMedCrossRef
61.
Zurück zum Zitat Sekizawa T, Openshaw H, Ohbo K et al. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154: 194–199 PubMedCrossRef Sekizawa T, Openshaw H, Ohbo K et al. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 154: 194–199 PubMedCrossRef
62.
Zurück zum Zitat Shefner JM, Cudkowicz ME, Schoenfeld D et al. (2004) A clinical trial of creatine in ALS. Neurology 63: 1656–1661 PubMed Shefner JM, Cudkowicz ME, Schoenfeld D et al. (2004) A clinical trial of creatine in ALS. Neurology 63: 1656–1661 PubMed
63.
Zurück zum Zitat Shibata N, Nagai R, Uchida K et al. (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97–104 PubMedCrossRef Shibata N, Nagai R, Uchida K et al. (2001) Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 917: 97–104 PubMedCrossRef
64.
Zurück zum Zitat Siklos L, Engelhardt J, Harati Y et al. (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 39: 203–216 PubMedCrossRef Siklos L, Engelhardt J, Harati Y et al. (1996) Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 39: 203–216 PubMedCrossRef
65.
Zurück zum Zitat Smith RG, Henry YK, Mattson MP, Appel SH (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696–699 PubMedCrossRef Smith RG, Henry YK, Mattson MP, Appel SH (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44: 696–699 PubMedCrossRef
66.
Zurück zum Zitat Storkebaum E, Lambrechts D, Dewerchin M et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85–92 PubMedCrossRef Storkebaum E, Lambrechts D, Dewerchin M et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85–92 PubMedCrossRef
67.
Zurück zum Zitat Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136–143 PubMedCrossRef Strong M, Rosenfeld J (2003) Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 4: 136–143 PubMedCrossRef
68.
Zurück zum Zitat Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64: 649–664 PubMedCrossRef Strong MJ, Kesavapany S, Pant HC (2005) The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J Neuropathol Exp Neurol 64: 649–664 PubMedCrossRef
69.
Zurück zum Zitat Sugai F, Yamamoto Y, Miyaguchi K et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179–3183 PubMedCrossRef Sugai F, Yamamoto Y, Miyaguchi K et al. (2004) Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 20: 3179–3183 PubMedCrossRef
70.
Zurück zum Zitat Tan CF, Eguchi H, Tagawa A et al. (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (Berl) 113: 535–542 Tan CF, Eguchi H, Tagawa A et al. (2007) TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol (Berl) 113: 535–542
71.
Zurück zum Zitat Traynor BJ, Bruijn L, Conwit R et al. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67: 20–27 PubMedCrossRef Traynor BJ, Bruijn L, Conwit R et al. (2006) Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67: 20–27 PubMedCrossRef
72.
Zurück zum Zitat Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067–1070 CrossRef Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W (2002) Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067–1070 CrossRef
73.
Zurück zum Zitat Van Muiswinkel FL, Kuiperij HB (2005) The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets 4: 267–281 CrossRef Van Muiswinkel FL, Kuiperij HB (2005) The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets 4: 267–281 CrossRef
74.
Zurück zum Zitat Wang R, Zhang D (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22: 2376–2380 PubMedCrossRef Wang R, Zhang D (2005) Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci 22: 2376–2380 PubMedCrossRef
75.
Zurück zum Zitat Wilms H, Sievers J, Dengler R et al. (2003) Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 144: 139–142 PubMedCrossRef Wilms H, Sievers J, Dengler R et al. (2003) Intrathecal synthesis of monocyte chemoattractant protein-1 (MCP-1) in amyotrophic lateral sclerosis: further evidence for microglial activation in neurodegeneration. J Neuroimmunol 144: 139–142 PubMedCrossRef
76.
Zurück zum Zitat Wu AS, Kiaei M, Aguirre N et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142–150 PubMedCrossRef Wu AS, Kiaei M, Aguirre N et al. (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142–150 PubMedCrossRef
77.
Zurück zum Zitat Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35: 419–432 PubMedCrossRef Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35: 419–432 PubMedCrossRef
78.
Zurück zum Zitat Yim MB, Kang JH, Yim HS et al. (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci U S A 93: 5709–5714 PubMedCrossRef Yim MB, Kang JH, Yim HS et al. (1996) A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc Natl Acad Sci U S A 93: 5709–5714 PubMedCrossRef
79.
Zurück zum Zitat Yoshihara T, Ishigaki S, Yamamoto M et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80: 158–167 PubMedCrossRef Yoshihara T, Ishigaki S, Yamamoto M et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80: 158–167 PubMedCrossRef
80.
Zurück zum Zitat Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267–270 PubMedCrossRef Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267–270 PubMedCrossRef
81.
Zurück zum Zitat Zhu S, Stavrovskaya IG, Drozda M et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74–78 PubMedCrossRef Zhu S, Stavrovskaya IG, Drozda M et al. (2002) Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74–78 PubMedCrossRef
Metadaten
Titel
Amyotrophe Lateralsklerose
Aktuelle klinische Studien und ihr pathogenetischer Hintergrund
verfasst von
Dr. K. Kollewe
R. Dengler
S. Petri
Publikationsdatum
01.06.2008
Verlag
Springer-Verlag
Erschienen in
Der Nervenarzt / Ausgabe 6/2008
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-007-2403-0